Wall Street expects sales of the drug to grow past $1 billion next year and top $2.5 billion by 2028, according to the data ...

Explore the role of preclinical MRI in studying neurological diseases, with a focus on advanced cellular and molecular ...

Johnson & Johnson acquires Intra-Cellular Therapies for $14.6 billion. The biggest driver was the rights Caplyta which has ...

Pharmaceutical giants have recently shown new enthusiasm for mental-health treatments with vast but unrealized promise.

Intra-Cellular Therapies Inc (ITCI) stock saw a decline, ending the day at $126.2 which represents a decrease of $-0.06 or -0.05% from the prior close of $126.26. The stock opened at $126.65 and ...

A phase 1 clinical trial co-led by researchers at Washington University School of Medicine in St. Louis found that a new type ...

Shares of Intra-Cellular rose 34% to $128 in afternoon trading, while J&J rose 1.5%. The deal would allow J&J to gain access to Intra-Cellular's oral therapy, Caplyta, which is approved in the U.S ...

Intra-Cellular Therapies makes Caplyta, a once-daily pill for adults with schizophrenia and bipolar-related depression ...

J&J will buy all of Intra-Cellular's shares for $132 apiece, representing a 39% premium to their Friday closing price. Shares ...

The emergency satellite connectivity has ferried 96,000 text messages to residents in fire-stricken areas of Los Angeles ...

"Berries offer an exceptional combination of nutrients and compounds that support longevity and healthy aging. They’re ...

As the first and most advanced cellular therapy centre in the UAE, the UC-MSCs used for this therapy were fully produced at ADSCC’s advanced laboratories ...